Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative diseases, primarily Alzheimer’s and Parkinson’s. Its lead product candidate, buntanetap, is an oral small molecule designed to inhibit multiple neurotoxic proteins involved in disease progression, aiming to improve cognition and motor function. Annovis targets large aging populations with unmet medical needs through a drug development platform focused on disease-modifying treatments for chronic and acute neurodegeneration.
This description was generated via AI from an annual report. Updated about 1 year ago.